Last reviewed 2026-04-20 · How we verify

Dexamethasone ophthalmic insert 0.4 mg

Dexamethasone ophthalmic insert 0.4 mg, marketed by William Wiley, MD, holds a niche position in the ophthalmic anti-inflammatory market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of disclosed revenue data, which may indicate limited market penetration or sales volume.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
• Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
• DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
• In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (PHASE4)
• Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (EARLY_PHASE1)
• Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) (PHASE4)
• Pharmacokinetics of Aqueous Dexamethasone (PHASE4)
• The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dexamethasone ophthalmic insert 0.4 mg CI brief — competitive landscape report
• Dexamethasone ophthalmic insert 0.4 mg updates RSS · CI watch RSS
• William Wiley, MD portfolio CI